参考文献/References:
[1] Sperling RA, Johnson KA. Dementia: new criteria but no new treatments[J]. Lancet Neurol, 2012, 11(1): 4-5.
[2] Mantzavinos V, Alexiou A. Biomarkers for alzheimer's disease diagnosis[J]. Curr Alzheimer Res, 2017, 14(11): 1149-1154.
[3] Jack CR. A/T/N:an unbiased descriptive classification scheme for alzheimer disease biomarkers[J]. Neurology, 2016, 87(5): 539-547.
[4] Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer's disease Concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts[J]. Alzheimers Dement, 2018, 14(11): 1470-1481.
[5] Pase MP, Beiser AS, Himali JJ, et al. Assessment of plasma total Tau level as a predictive biomarker for dementia and related endophenotypes[J]. JAMA Neurol, 2019, 76(5): 598-606.
[6] Lövheim H, Elgh F, Johansson A, et al. Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease[J]. Alzheimers Dement, 2017, 13(7): 778-782.
[7] Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease[J]. Clin Biochem, 2019, 72: 87-89.
[8] 国家卫生健康委办公厅,中华人民共和国国家卫生健康委员会.阿尔茨海默病的诊疗规范(2020年版)[J].全科医学临床与教育,2021,19(1):4-6.
[9] White CS, Lawrence CB, Brough D, et al. Inflammasomes as therapeutic targets for Alzheimer's disease[J]. Brain Pathol, 2017, 27(2): 223-234.
[10] Saresella M, Marventano I, Piancone F, et al. IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment[J]. J Neuroinflammation, 2020, 17(1): 174.
[11] FuAK, Hung KW, Yuen MY, et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline[J]. Proc Natl Acad Sci U S A, 2016, 113(19): E2705-E2713.
[12] Italiani P, Puxeddu I, Napoletano S, et al. Circulating levels of IL-1 family cytokines and receptors in Alzheimer's disease: new markers of disease progression?[J]. J Neuroinflammation, 2018, 15(1): 342.
[13] Xiong Z, Thangavel R, Kempuraj D, et al. Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain[J]. J Alzheimers Dis, 2014, 40(2): 297-308.
[14] Xu M, Wu G. The clinical significance of serum IL-33 and sST2 alterations in the Post-Stroke depression[J]. J Multidiscip Healthc, 2021, 14(14): 2009-2015.
[15] Liu X, Xiao Y, Pan Y, et al. The role of the IL-33/ST2 axis in autoimmune disorders: Friend or foe?[J]. Cytokine Growth Factor Rev, 2019, 50: 60-74.
[16] Abd RM, Chin VK, Abd Majid R, et al. Critical roles of IL-33/ST2 pathway in neurological disorders[J]. Mediators Inflamm, 2018, 5346413.
[17] Browne TC, Mcquillan K, Mcmanus RM, et al. IFN-γ production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of alzheimer's disease[J]. J Immunol, 2013, 190(5): 2241-2251.